

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Veterinary Vaccinology

edited by

P.-P. Pastoret
*Université de Liège,
 Department of Immunology-Vaccinology,
 Faculty of Veterinary Medicine,
 Sart-Tilman
 Liège, Belgium*

J. Blancou
*Office International des Epizooties,
 Paris, France*

P. Vannier
*CNEVA
 Ploufragan, France*

C. Verschueren
*FEDESA/COMISA
 Brussels, Belgium*



ELSEVIER

AMSTERDAM - LAUSANNE - NEW YORK - OXFORD - SHANNON - TOKYO

ELSEVIER SCIENCE B.V.
Sara Burgerhartstraat 25
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

© 1997 Elsevier Science B.V. All rights reserved.

This work is protected under copyright by Elsevier Science, and the following terms and conditions apply to its use:

Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier's home page (<http://www.elsevier.nl>), selecting first 'Custom Permissions Query Form'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 171 631 5555; fax: (+44) 171 631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Tables of contents may be reproduced for internal circulation, but permission of Elsevier Science is required for external resale or distribution of such material. Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 1997

Second impression 1999

Library of Congress Cataloging in Publication Data

Veterinary vaccinology / edited by P.-P. Pastoret ... [et al.].

P. cm.

Includes bibliographical references and index.

ISBN 0-444-81968-1

1. Veterinary vaccines. 2. Vaccination of animals. I. Pastoret, Paul-Pierre.

SF918.V32V48 1997

628.089'47--dc21

97-11158

CIP

ISBN: 0 444 81968 1

⊗ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Printed in The Netherlands.

TABLE 4

Peptide vaccines for Parvo virus

	Antiviral activity*			Protection in target animals**		
	ELISA	NT	T cell	single dose	Double dose	Control
Langeveld et al. (1994)	+	+/-	-	1/6	9/9	0/4
Langeveld et al. (in prep.)	+	-	nt		nt	0/6

*nt = Not tested; + = activity present; - = no activity; +/- = activity in some individual animals.

**Ratio = number of protected animals/number of total animals.

which is shown to be highly conserved between strains and types, a peptide has been defined which readily induces full protection against disease in dogs after CPV infection using two vaccinations. Mink were protected with the same peptide vaccine against another parvovirus (mink enteritis virus) after a single vaccination. This appears to be the first example of a peptide vaccine which seems as effective as the classical vaccine based on whole virus.

9.5. CONCLUSION

From this, we speculate that it will be possible to develop effective peptide vaccine against other DNA viruses, notably those depending on humoral immunity for protection.

We further speculate that full protective peptide vaccines as effective as classical ones, are feasible in case of RNA viruses, like FMDV, if, in addition to the loop-peptide a peptide can be defined and constructed which represents one of the additional discrete neutralizing antigenic sites of FMDV.

PART 10. OTHER TYPES OF VACCINES (i.e., WITH CYTOKINES) W. Strube

The immune response can be divided into two functional groups: the innate or primitive immune system and the adaptive immune system (Büttner, 1993). The innate immune system, which represents the first barrier in the combat against infectious diseases, is mediated by antigen non-specific actions of neutrophils, natural killer cells, macrophages and by soluble factors like the complement system. The adaptive immune system is represented by the antigen-specific B- and T-cells. Both parts of the immune response are modulated by, and interact through, cytokines, including interleukins (IL), interferons (IFN), colony stimulating factors (CSF) and tumour necrosis factors (TNF) (Roitt et al., 1989). IL-1 is synthesized by antigen-presenting cells and contribute to T- and B-cell stimulation (Mizel, 1982). IL-2, IL-4, IL-5, and IFN-gamma are involved in clonal proliferation and differentiation of immune cells (Kelso, 1989; O'Garra et al., 1988). IL-2 contributes especially to proliferation, differentiation and cytotoxic activity of T-cells (Farrar et al., 1982). IFN-gamma stimulates macrophages and induces expression of MHC class II (Roitt et al., 1989). Due to their physiological function in the immune system cytokines,

CATEGORIES OF PRODUCTS

when combined or applied simultaneously with immunogens, may influence immunogenicity of vaccines. Therefore, cytokines were evaluated as 'natural' adjuvants in various vaccine models. Schijns and co-workers compared different cytokines in a rabies challenge model in mice (Schijns et al., 1994). Whereas TNF-alpha and IL-1-alpha, when applied shortly before rabies vaccination only marginally induced protection against challenge infection, IFN-gamma and IL-2, respectively, markedly increased immunogenicity following vaccination. Combined administration of IFN-gamma and IL-2 synergistically enhanced formation of neutralizing antibodies following rabies vaccination but did not further increase resistance to challenge. Reddy and colleagues reported that administration of recombinant bovine IL-1 β in combination with a BHV-1 live attenuated vaccine increased the vaccine induced cytotoxic immune response in cattle and reduced challenge virus replication following experimental infection (Reddy et al., 1990). The same team also tested recombinant bovine IL-2 as an adjuvant of a live BHV1 vaccine (Reddy et al., 1989). Five consecutive applications of IL-2 significantly enhanced humoral and cellular immune responses as well as clinical protection following immunization with a live attenuated BHV1 vaccine in cattle. No additive effect was observed when IL-1 and IL-2 were administered together (Reddy et al., 1993). Hughes and co-workers confirmed the efficacy of IL-2 in cattle and demonstrated that multiple injections of IL-2 following vaccination with a BHV1 glycoprotein gD vaccine significantly increased BHV1 specific cytotoxicity and gD specific lymphocyte proliferation response compared to vaccinated animals that were not treated with IL-2 (Hughes et al., 1991). In the ovine system, IL-1 and 2, as well as TNF, have been produced by recombinant DNA techniques (Fash et al., 1993). Adjuvant studies using avidin as a model antigen demonstrated that ovine IL-1 significantly increased antibody formation in sheep (Andrews et al., 1994). The use of cytokines as natural adjuvants may even allow the stimulation of specific immunoglobulin classes. The use of a recombinant vaccinia virus expressing murine IL-5 and influenza HA protein demonstrated that IL-5 selectively enhanced mucosal IgA response specific for HA in mice (Ramsay and Kohonen-Corish, 1993). In summary, all these results indicated that cytokines may indeed be used to improve efficacy of vaccines. Babiuk's group has already constructed a molecular chimera of a *Pasteurella haemolytica* leukotoxin and IL-2 (Hughes et al., 1992). Because of safety, efficacy and manufacturing aspects, such antigen-cytokine complexes may represent future vaccines.

PART 11. FUTURE TYPES OF VACCINATION

R.H. Meloen

This section deals with most of the veterinary vaccines we may expect in the future. Presently, two sorts are emerging: one that deals with vaccines against 'self' protein, notably hormones. These vaccines will be dealt with elsewhere. The other one deals with DNA vaccination.

11.1. DNA VACCINATION

DNA plasmids can be used for DNA vaccination (Davis et al., 1993; Robinson et al., 1993) and have a number of appealing advantages: large proteins can be easily expressed in eukaryotic cells, vaccine design is relatively easy, the vaccine itself is